Therapeutic vaccines for tuberculosis—A systematic review

Gröschel, Matthias I.; Prabowo, Satria A.; Cardona, Père-Joan; Stanford, J. L.; Werf, Tjip S. van der

doi:10.1016/j.vaccine.2014.03.047

Cited by 66 publications

(44 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These vaccines modulate the immune system to help it target persisting and dormant TB bacilli thereby improving the sterilizing capacity of the human immune system [120]. To date, several phase II and III studies have been performed focusing on safety, immunogenicity, and improved treatment outcome.…”

Section: Five-year Viewmentioning

confidence: 99%

Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers

Alffenaar

Akkerman

Anthony

et al. 2016

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Introduction: Success rates for treatment of extensively drug resistant tuberculosis (XDR-TB) are low due to limited treatment options, delayed diagnosis and inadequate health care infrastructure. Areas covered: This review analyses existing programmes of prevention, diagnosis and treatment of XDR-TB. Improved diagnostic procedures and rapid molecular tests help to select appropriate drugs and dosages. Drugs dosages can be further tailored to the specific conditions of the patient based on quantitative susceptibility testing of the M. tuberculosis isolate and use of therapeutic drug monitoring. Pharmacovigilance is important for preserving activity of the novel drugs bedaquiline and delamanid. Furthermore, biomarkers of treatment response must be developed and validated to guide therapeutic decisions. Expert commentary: Given the currently poor treatment outcomes and the association of XDR-TB with HIV in endemic regions, a more patient oriented approach regarding diagnostics, drug selection and tailoring and treatment evaluation will improve treatment outcome. The different areas of expertise should be covered by a multidisciplinary team and may involve the transition of patients from hospitalized to home or community-based treatment.

show abstract

Section: Five-year Viewmentioning

confidence: 99%

Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers

Alffenaar

Akkerman

Anthony

et al. 2016

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

show abstract

“…Anti-tuberculous therapy usually stretches over a few months, which makes patient compliance difficult [100,20] Resistant TB has become a major public health challenge worldwide, since progress in TB treatment has declined, due to increasingly fewer patients being fully cured by pharmacotherapy [104,38,50,27,105]. This overall has led to increased research into the development of TB vaccines, and as a result promising vaccines are in the pipeline [106].…”

Section: Current Treatment Regimens Of Cutaneous Tuberculosismentioning

confidence: 99%

Cutaneous tuberculosis overview and current treatment regimens

2015

View full text Add to dashboard Cite

“…and a lysate vaccine from AnHui Zhifei Longcom of China. 43 Interestingly, a recent clinical trail from Tanzania has demonstrated that the protective effectiveness of M. vaccae against TB was observed among HIV-infected and BCG-vaccinated adults with CD4 counts of not less than 200 cells/ml, suggesting that M. vaccae can be used as a preventive vaccine for TB. 44 Further clinical studies on the usefulness of M. vaccae for preventing infant population from TB infection are warranted.…”

Section: Mycobacterium Vaccaementioning

confidence: 99%

Current status of new tuberculosis vaccine in children

Pang

Zhao

Cohen³

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Pediatric tuberculosis contributes significantly to the burden of TB disease worldwide. In order to achieve the goal of eliminating TB by 2050, an effective TB vaccine is urgently needed to prevent TB transmission in children. BCG vaccination can protect children from the severe types of TB such as TB meningitis and miliary TB, while its efficacy against pediatric pulmonary TB ranged from no protection to very high protection. In recent decades, multiple new vaccine candidates have been developed, and shown encouraging safety and immunogenicity in the preclinical experiments. However, the limited data on protective efficacy in infants evaluated by clinical trials has been disappointing, an example being MVA85A. To date, no vaccine has been shown to be clinically safer and more effective than the presently licensed BCG vaccine. Hence, before a new vaccine is developed with more promising efficacy, we must reconsider how to better use the current BCG vaccine to maximize its effectiveness in children.

show abstract

Therapeutic vaccines for tuberculosis—A systematic review

Cited by 66 publications

References 69 publications

Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers

Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers

Cutaneous tuberculosis overview and current treatment regimens

Current status of new tuberculosis vaccine in children

Contact Info

Product

Resources

About